Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300924 · ClinicalTrials.gov registry record · Phase 3
A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine
A Phase 3 study of Migraine, sponsored by Diamond Headache Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 7
- Study locations
NCT00300924 is a Phase 3 study of Migraine that has completed, run by Diamond Headache Clinic. The registered enrollment target is 200 participants, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (44% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT00300924, a Phase 3 study of Migraine, has completed, sponsored by Diamond Headache Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test an experimental drug combination of two medications currently approved by the Food and Drug Administration (FDA) for migraine headache or other pain. These are called rizatriptan given with acetaminophen.
Conditions Studied
Interventions
- DRUG Rizatriptan co-administered with Acetaminophen
Study Locations (7)
Missouri
- Clinvest - Springfield
- Mercy Health Research - St Louis
California
- SanFrancisco Headache Clinic - San Francisco
Illinois
- Diamond Headache Clinic - Chicago
Michigan
- Westside Family Medical Center - Kalamazoo
New York
- Elkind Headache Center - Mount Vernon
Ohio
- ClinExcel - West Chester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300924
The ClinicalTrials.gov registry entry for NCT00300924 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (44% lower). The listed sponsor is Diamond Headache Clinic, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Rizatriptan co-administered with Acetaminophen is the first listed.
NCT00300924 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Missouri, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00300924 about?
NCT00300924 is a clinical study titled "A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine". The purpose of this study is to test an experimental drug combination of two medications currently approved by the Food and Drug Administration (FDA) for migraine headache or other pain. These are called rizatriptan given with acetaminophen.
What is the current status of trial NCT00300924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2006-03. Estimated completion is 2007-01.
What conditions does trial NCT00300924 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT00300924?
The interventions under investigation include: Rizatriptan co-administered with Acetaminophen (DRUG).
Who is sponsoring clinical trial NCT00300924?
This trial is sponsored by Diamond Headache Clinic, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00300924 being conducted?
This trial has 7 study locations across California, Illinois, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.